| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xin-Jue Shan, Dan Kang, Zhe Chen, Shi-Yu Zhang, Chun-Xiang Li. [Systematic review and Meta-analysis of efficacy and safety of Shumian Capsules in treatment of insomnia]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. vol 49. issue 1. 2024-02-25. PMID:38403359. |
in addition, shumian capsules had an advantage in treating insomnia complicated with depression in terms of hamd score(p<0.000 1) and reducing the serum levels of 5-ht, tsh, t3, and t4 in insomnia patients(p<0.05). |
2024-02-25 |
2024-02-28 |
Not clear |
| Michael Frazure, In Morimoto, Nathan Fielder, Nicholas Mellen, Kimberly Iceman, Teresa Pitt. Serotonin therapies for opioid-induced disordered swallow and respiratory depression. Journal of applied physiology (Bethesda, Md. : 1985). 2024-02-22. PMID:38385184. |
serotonin therapies for opioid-induced disordered swallow and respiratory depression. |
2024-02-22 |
2024-02-24 |
rat |
| Darya Rostam Ahme. Letter to the editor concerning: "The serotonin theory of depression: a systematic umbrella review of the evidence". Molecular psychiatry. 2024-02-20. PMID:38374358. |
letter to the editor concerning: "the serotonin theory of depression: a systematic umbrella review of the evidence". |
2024-02-20 |
2024-02-22 |
Not clear |
| Danilo Arnone, Toby Wise, Paul B Fitzgerald, Catherine J Harme. The involvement of serotonin in major depression: nescience in disguise? Molecular psychiatry. 2024-02-20. PMID:38374356. |
the involvement of serotonin in major depression: nescience in disguise? |
2024-02-20 |
2024-02-22 |
Not clear |
| Konstantinos N Fountoulakis, Eva Maria Tsapaki. Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. Molecular psychiatry. 2024-02-20. PMID:38374355. |
neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. |
2024-02-20 |
2024-02-22 |
Not clear |
| Andrew L Smith, Andre F Carvalho, Marco Solm. Methodological concerns in umbrella review of serotonin and depression. Molecular psychiatry. 2024-02-20. PMID:38374357. |
methodological concerns in umbrella review of serotonin and depression. |
2024-02-20 |
2024-02-22 |
Not clear |
| Diksha Choudhary, Bhupinder Kumar, Rajwinder Kau. Nitrogen-containing heterocyclic compounds: A ray of hope in depression? Chemical biology & drug design. vol 103. issue 2. 2024-02-16. PMID:38361139. |
drugs that are currently being used for the management of various types of depression include selective serotonin reuptake inhibitors, tricyclic antidepressants, atypical antidepressants, serotonin, noradrenaline reuptake inhibitors, etc. |
2024-02-16 |
2024-02-18 |
Not clear |
| Kazi Ishtiak-Ahmed, Christopher Rohde, Christian Otte, Christiane Gasse, Ole Köhler-Forsber. Comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for depression in 43,061 older adults with chronic somatic diseases: A Danish target trial emulation study. General hospital psychiatry. vol 87. 2024-02-14. PMID:38354442. |
comparative effectiveness of selective serotonin reuptake inhibitors (ssris) for depression in 43,061 older adults with chronic somatic diseases: a danish target trial emulation study. |
2024-02-14 |
2024-02-17 |
Not clear |
| Kazi Ishtiak-Ahmed, Christopher Rohde, Christian Otte, Christiane Gasse, Ole Köhler-Forsber. Comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) for depression in 43,061 older adults with chronic somatic diseases: A Danish target trial emulation study. General hospital psychiatry. vol 87. 2024-02-14. PMID:38354442. |
to investigate the comparative effectiveness of commonly used selective serotonin reuptake inhibitors (ssris) for comorbid depression in older adults with chronic somatic diseases by applying a target-trial-emulation framework. |
2024-02-14 |
2024-02-17 |
Not clear |
| Tommaso Barba, Hannes Kettner, Caterina Radu, Joseph M Peill, Leor Roseman, David J Nutt, David Erritzoe, Robin Carhart-Harris, Bruna Giribald. Psychedelics and sexual functioning: a mixed-methods study. Scientific reports. vol 14. issue 1. 2024-02-07. PMID:38326446. |
it is also a common side effect of selective serotonin reuptake inhibitors (ssris), a first line treatment for depression. |
2024-02-07 |
2024-02-10 |
human |
| Yi Li, Yan Yin, Yingyi Yu, Xiwen Hu, XiaoYan Liu, Sha W. The potential predictors for treatment-resistance depression after selective serotonin reuptake inhibitors therapy in Han Chinese: A resting-state functional magnetic resonance imaging study. Early intervention in psychiatry. 2024-02-06. PMID:38320861. |
the potential predictors for treatment-resistance depression after selective serotonin reuptake inhibitors therapy in han chinese: a resting-state functional magnetic resonance imaging study. |
2024-02-06 |
2024-02-09 |
Not clear |
| Konstantinos N Fountoulakis, Mauricio Tohen, Carlos A Zarat. Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 81. 2024-02-04. PMID:38310714. |
the original model suggests that a constellation of effects on different receptors is necessary, but refinements, including the present study, suggest that the inhibition of the serotonin reuptake at the first level, the 5ht-2a blockade at the second level, and the norepinephrine alpha-1 receptors blockade at a third level in combination with d1 blockade contribute to the antidepressant effect in acute bipolar depression. |
2024-02-04 |
2024-02-07 |
Not clear |
| Sandra Ledesma-Corvi, Jordi Jornet-Plaza, Laura Gálvez-Melero, M Julia García-Fuste. Novel rapid treatment options for adolescent depression. Pharmacological research. 2024-02-03. PMID:38309382. |
there is an urgent need for novel fast-acting antidepressants for adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved for that age (i.e., fluoxetine or escitalopram) take weeks to work. |
2024-02-03 |
2024-02-06 |
Not clear |
| Sebastián García Menéndez, Walter Manuch. Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health. Current pharmaceutical design. 2024-02-02. PMID:38303529. |
lastly, its role in intestinal microbiota and serotonin synthesis contributes to psychiatric disorders like schizophrenia and depression. |
2024-02-02 |
2024-02-04 |
Not clear |
| Kelly E Dunham, B Jill Vento. Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression. Analytical and bioanalytical chemistry. 2024-01-30. PMID:38289354. |
three neurotransmitters: serotonin, histamine, and glutamate, have been proposed to be key mediators of depression. |
2024-01-30 |
2024-02-01 |
Not clear |
| Elizabeth Lovegrove, Alice Maidwell-Smith, Beth Stuart, Miriam Sante. SSRIs in women of reproductive age; a systematic review of local formularies. BJGP open. 2024-01-25. PMID:38272494. |
depression is the second most common chronic condition affecting women of reproductive age; 23.4% of women enter pregnancy with depression and use of selective serotonin reuptake inhibitors (ssris) in pregnancy is often necessary for maternal wellbeing. |
2024-01-25 |
2024-01-28 |
Not clear |
| Stefano Comai, Nicolas Nunez, Tobias Atkin, Maykel F Ghabrash, Rita Zakarian, Allan Fielding, Marie Saint-Laurent, Nancy Low, Garrett Sauber, Eugenio Ragazzi, Cecilia J Hillard, Gabriella Gobb. Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms. BMC medicine. vol 22. issue 1. 2024-01-25. PMID:38273283. |
the endocannabinoid (ecb) system and the serotonin (5-ht) are both implicated in the severity of the depression. |
2024-01-25 |
2024-01-28 |
Not clear |
| Sounak Bagchi, Ehsan Nozohouri, Yeseul Ahn, Dhavalkumar Patel, Ulrich Bickel, Vardan T Karamya. Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration. Pharmaceutics. vol 16. issue 1. 2024-01-23. PMID:38258064. |
milnacipran is a dual serotonin and norepinephrine reuptake inhibitor, clinically used for the treatment of major depression or fibromyalgia. |
2024-01-23 |
2024-01-25 |
mouse |
| Mariko Nakamura, Akira Yoshimi, Tatsuya Tokura, Hiroyuki Kimura, Shinichi Kishi, Tomoya Miyauchi, Kunihiro Iwamoto, Mikiko Ito, Aiji Sato-Boku, Akihiro Mouri, Toshitaka Nabeshima, Norio Ozaki, Yukihiro Nod. Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein. Pain. 2024-01-16. PMID:38227563. |
as the result, decrease of plasma serotonin concentrations may be related to the efficacy of dlx in relieving pain and depression in cop patients. |
2024-01-16 |
2024-01-19 |
Not clear |
| Nune Darbinian, Nana Merabova, Gabriel Tatevosian, Mary Morrison, Armine Darbinyan, Huaqing Zhao, Laura Goetzl, Michael Edgar Selze. Biomarkers of Affective Dysregulation Associated with In Utero Exposure to EtOH. Cells. vol 13. issue 1. 2024-01-11. PMID:38201206. |
many women who use alcohol (ethanol, etoh) during pregnancy suffer from depression and take selective serotonin reuptake inhibitors (ssris), which might influence these monoaminergic pathways in the fetus. |
2024-01-11 |
2024-01-13 |
Not clear |